An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Curie Therapeutics Appoints Karen Smith, M.D., Ph.D., as Independent Board Director
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Curie Therapeutics has appointed Dr. Karen Smith to its Board of Directors to enhance its expertise in oncology drug development. CEO Simon Read expressed that her diverse background in medicine, law, and business will be invaluable as Curie advances its precision radiopharmaceuticals. Dr. Smith brings considerable experience from leading global product launches in major pharmaceutical companies and biotech firms. Curie aims to innovate cancer treatments, focusing on targeted radiopharmaceuticals designed for high potency and stability.
Positive
Appointment of Dr. Karen Smith to the Board of Directors will enhance strategic oversight.
Dr. Smith's extensive experience in oncology and drug development could accelerate product pipeline advancement.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, announced today that it has appointed Karen Smith, M.D., Ph.D., M.B.A., L.L.M., to its Board of Directors.
“It is with much excitement that we welcome Karen to our Board of Directors to provide additional diversity of thought and development experience,” said Simon Read, Curie’s CEO and founder. “Karen’s depth of knowledge in oncology drug development, experience on platform and asset-focused company boards, and background spanning medicine, law, and business, will serve us well as we advance our first precision radiopharmaceuticals into the clinic.”
“With a team of seasoned experts across its core capabilities and a mission to deliver an oncology drug profile that has not yet been achieved with existing modalities, Curie is uniquely poised to usher in a new era for precision radiopharmaceuticals,” said Dr. Smith. “Together we’ll build and advance a pipeline of radiopharmaceuticals designed to maximize potency, selectivity, and stability, while also achieving rapid systemic clearance. I believe Curie’s approach has the potential to result in powerful, novel treatments for patients suffering from solid tumors of high unmet need.”
Dr. Smith has overseen numerous trials and regulatory approvals leading to global product launches of small molecules, biologics and devices across oncology and other therapeutic areas. She is an accomplished executive who has led departments within large pharma (Allergan, Astra-Zeneca, Bristol Myers Squibb), and served as CMO or CEO at notable biotech companies (Jazz, ECI, Novosteo). She currently serves on the boards of Antares Pharma, Sangamo Therapeutics and Emyria Ltd. and has helped guide several successful corporate exits through acquisition (Forward Pharma, Sucampo Pharma, Acceleron Pharma). Dr Smith’s credentials include a B.App.Sc. with a double major in Biotechnology and Haematology; an M.D.; a Ph.D. in oncology molecular genetics; an M.B.A. and a Master of Law (L.L.M.).
About Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie’s mission is to revolutionize the use of radiomedicines in cancer. Learn more at www.curietherapeutics.com.
